Figure S5 from A Phase II Trial of Guadecitabine Plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy Hyo Sik Jang , Galen Hostetter , Alexander W. Macfarlane , Zachary Madaj , Eric A. Ross , Toshinori Hinoue , Justin R. Kulchycki , Ryan S. Burgos , Mahvish Tafseer , R. Katherine Alpaugh , Candice L. Schwebel , Rutika Kokate , Daniel M. Geynisman , Matthew R. Zibelman , Pooja Ghatalia , Peter W. Nichols , Woonbok Chung , Jozef Madzo , Noah M. Hahn , David I. Quinn , Jean‐Pierre J. Issa , Michael J. Topper , Stephen B. Baylin , Hui Shen , Kerry S. Campbell , Peter A. Jones , Elizabeth R. Plimack openalex
关键词
Urothelial Carcinoma, Tumor Mutational Burden, Cancer Immunoediting, Metastatic Tumors, Tumor Microenvironment
AI 理解论文
溯源树
样例
